Rocco Cassetta Brooklyn New York (@medicroc) profile picture

retired NYC medic, single father two little boys. Sense of humor can melt my ice cold heart.

NYC
Joined February 2011
Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)Photo by Rocco Cassetta Brooklyn New York (@medicroc)
Anthropic shares fall 6% as of 2:03am EST #Anthropic
8
Nasdaq futures down 456 points. I guess no Jensen yet
22
Raise your hand if you're excited about Anthropic going public Thrusday. Wow! An impressive $33 bil in revenue in 2026! Damned impressive until u try to figure out how they are gonna come up with the $ 500 bil in obligations that come crashing the door by end 2030.
22
Re: The petition to bring Jensen Huang back to Nvidia Sam Alman's only crime when he was fired was that he was an arrogant son of a b-tch Jensen Huang in contrast carries more baggage than a non-stop flight from New York to Tokyo
40
Idc if the Messiah signs that position AI's Gangster in Chief Jensen Huang is not coming back. Way too much baggage worst being all those gpus smuggled into China. So tuff but wait till they get him in front of congress. They'll have to smack him once to talk and twice to shut up
24
I recall you saying to watch for the first company to hesitate on throwing more capex into the pile. I bet not even you thought it would be Nvidia lmao @edzitron
10
Apparently that National Weather Service thing was bullsh-t Sorry
NOAA just posted an alert confirming that there is NO nationwide radar or network outage, time stamped to a few minutes ago. Unfortunately, the fake news about a non-existent outage continues rapidly spreading including through mainstream news outlets. nco.ncep.noaa.gov/status/mes…
49
Rocco Cassetta Brooklyn New York retweeted
NOAA just posted an alert confirming that there is NO nationwide radar or network outage, time stamped to a few minutes ago. Unfortunately, the fake news about a non-existent outage continues rapidly spreading including through mainstream news outlets. nco.ncep.noaa.gov/status/mes…
10
89
11
288
33,088
The National Weather Service has reported experiencing nationwide internet and communications failures Sounds loke.we got hacked big time
66
Guy in Starbucks today with a friend explaining how the AI Bubble will be the most destructive bubble in history. Little did he realize the bond market was crouched behind him sawing the two back legs off his chair
35
A message to Jenson Huang CEO of Nvidia: Your failure to perform what every boy comes to know by the age of 14- namely The Self Abuse Soliliquay- cost investors over $200 billion dollars today making you one of the biggest jerkoff's in history
47
Jenson Huang , the very high profile CEO of Nvidia busted not only for cheating on his wife but having the extreme good fortune to pick a Chinese spy as his screwee! Did he think he wouldnt be discovered? Please I bet theres someone out there that knows the avg weight of his crap
1
57
Was X hacked? My feed is going bezerk with doomsday shit
1
1
45
Rocco Cassetta Brooklyn New York retweeted
Trump promised to “Drain the Swamp.” Then he made $2 billion off the presidency. He promised to “Make America Healthy Again.” Then he took healthcare from 15 million people. He promised “No More Wars.” Then he attacked Iran. Say NO to Trump. Say NO to a Republican Congress.
1
14
The AI Bubble has arrived! They tried to avert you attention with all this " AI IS gonna exterminate us all". No the only thing thats going to be exterminated are shareholders equity, police, fire, paramedic , teacher pension funds and your 401ks
1
1
46
Rocco Cassetta Brooklyn New York retweeted
Did the war just end or something??? $HIMS $ASST $ASTS $NAUT $IBRX
11
3
50
6,136
Rocco Cassetta Brooklyn New York retweeted
We will defeat cancer and extend human life span dramatically. Mybe even reverse the clock by undoing the damage done to us. $IBRX
We were honored to join the oncology community at #ESMO26 in Madrid, sharing progress in our mission to harness the power of immunotherapy. The energy and collaboration throughout the week reinforced what drives us: advancing innovative treatments with the goal of improving outcomes and quality of life for patients worldwide. Thank you to our team and collaborators who make this work possible.
1
3
1
76
1,424
Rocco Cassetta Brooklyn New York retweeted
$IBRX: database locked Oct 21, topline guided for November. This readout decides whether ImmunityBio becomes a BCG-naive company or stays a niche one. Cramer called it his "very good spec" on Monday, the stock bounced ~10% Tuesday, and retail is split. Here's what we already know, the bar the trial walks into, and what's priced in. THE TRIAL QUILT-2.005: Anktiva + BCG vs BCG alone, 366 randomized patients, BCG-naive NMIBC with carcinoma in situ, with or without papillary disease. Enrollment closed in February. Primary endpoint: complete response rate. Key secondary: duration of response. sBLA still guided for Q4 2026. WHAT WE ALREADY KNOW An FDA-requested interim on a limited early sample showed CR maintained in 85% vs 57% of patients at 6 months, and 84% vs 52% at 9 months. The difference in duration of CR at 9 months: p=0.0455. In March, the IDMC looked at 183 evaluable patients and said the trial was "adequately powered to detect the pre-specified difference." No extra patients needed. Two caveats. The company itself says no conclusions can be drawn from the interim. And it never disclosed the effect size the trial is powered for. Note the control arm: 52% at 9 months, well below the ~70% CR rates in older BCG literature. The final will show whether that gap holds over 366 patients or narrows. THE BAR MOVED IN MAY On May 28, the FDA approved AstraZeneca's Imfinzi + BCG in BCG-naive high-risk NMIBC, on POTOMAC: 1,018 patients, disease-free survival HR 0.68. Pfizer's CREST (sasanlimab + BCG) hit event-free survival HR 0.68 in 1,055 patients. ALBAN (atezolizumab + BCG) was negative, HR 0.98. Different endpoints, no head-to-head, so this isn't "smaller trial = worse trial." But the precedent in this setting is recurrence-free time over years, and QUILT-2.005 measures CR rate. Clean data still leaves a real question about what label it supports. WHERE ANKTIVA CAN WIN Tolerability. In POTOMAC, grade 3–4 treatment-related AEs ran 21% vs 4% with BCG alone. Checkpoint add-ons bring systemic immune toxicity and pull medical oncologists into what is today a urologist's disease. Anktiva goes into the bladder. A durable CR gain with safety close to BCG would make it the urologist-friendly option. That's the bull case. It still has to show up in the final safety table. WHAT'S IN THE PRICE ~$8.60 × 1.06B shares ≈ $9.1B market cap. Add the related-party convertible ($480M principal, carried at $774M fair value) and the Oberland revenue-interest liability ($415M). Subtract $357M of cash and marketable securities (June 30). EV ≈ $9.7B on principal, ~$9.9B on fair value. Q2 product revenue: $50.7M, ~$203M annualized. That's ~48x EV/sales. Growth is real: H1 revenue was $94.8M, up 121%. Share count: 915.6M a year ago, 1.06B in July (+16%), with a $352M warrant liability on the balance sheet. At that multiple, BCG-naive expansion is the thesis, not an option on it. POSITIONING Short interest: ~123M shares, ~11.6% of shares outstanding, 7 days to cover (Oct 15). Stocktwits sentiment flipped to bearish this week while message volume jumped 274%. HOW I'LL READ THE TOPLINE Strong: CR rates for both arms with a clear absolute gap, durability past 12 months, safety close to BCG alone. Weak: "met its primary endpoint" with no BCG-arm number, a gap much smaller than the interim's, or a pivot to duration only. Then the sBLA: the indication they file for will tell you what they think the data supports. Three different bets here: does it work, will the FDA take it, and is it worth $9B+ if both go right. The data can be good and the stock can still disappoint. #BladderCancer #biotech
1
1
18
1,655
Rocco Cassetta Brooklyn New York retweeted
Here are the 8 biotech stocks: 1. $HIMS 2. $TEM 3. $IBRX 4. $NAUT 5. $ABCL 6. $BFLY 7. $RXRX 8. $PDSB
1
5
640
Biotechnology stocks are good bets at this time
I urge you to read this article. This year, biotech stocks will generate massive, generational wealth for investors. Here are five biotech stocks with the potential for 10-fold growth: 1) $IBRX
30